{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:18:01Z","timestamp":1791908281806,"version":"4.3.4"},"reference-count":83,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T00:00:00Z","timestamp":1693094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Nonalcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD) affects ~70% of patients with type 2 diabetes (T2D), with ~20% showing signs of advanced liver fibrosis. Patients with T2D are at an increased risk of developing cirrhosis, liver failure, and hepatocellular carcinoma and their liver-related mortality is doubled compared with non-diabetic individuals. Nonetheless, the condition is frequently overlooked and disease awareness is limited both among patients and among physicians. Given recent epidemiological evidence, clinical practice guidelines recommend screening for NAFLD\/MASLD and advanced liver fibrosis in patients with T2D. While many drugs are currently being tested for the treatment of NAFLD\/MASLD, none of them have yet received formal approval from regulatory agencies. However, several classes of antidiabetic drugs (namely pioglitazone, sodium-glucose transporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and multi-agonists) have shown favorable effects in terms of liver enzymes, liver fat content and, in some occasions, on histologic features such as inflammation and fibrosis. Therefore, diabetologists have the opportunity to actively treat NAFLD\/MASLD, with a concrete possibility of changing the natural history of the disease. In the present narrative review, we summarize evidence and clinical recommendations for NAFLD\/MAFLD screening in the setting of T2D, as well as on the effect of currently available glucose-lowering drugs on hepatic endpoints.<\/jats:p>","DOI":"10.3390\/jcm12175597","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T06:10:22Z","timestamp":1693203022000},"page":"5597","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2422-3041","authenticated-orcid":false,"given":"Stefano","family":"Ciardullo","sequence":"first","affiliation":[{"name":"Department of Medicine and Rehabilitation, Policlinico di Monza, Via Modigliani 10, 20900 Monza, MB, Italy"},{"name":"Department of Medicine and Surgery, University of Milano Bicocca, 20126 Milan, MI, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Vergani","sequence":"additional","affiliation":[{"name":"Department of Medicine and Rehabilitation, Policlinico di Monza, Via Modigliani 10, 20900 Monza, MB, Italy"},{"name":"Department of Medicine and Surgery, University of Milano Bicocca, 20126 Milan, MI, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3024-0457","authenticated-orcid":false,"given":"Gianluca","family":"Perseghin","sequence":"additional","affiliation":[{"name":"Department of Medicine and Rehabilitation, Policlinico di Monza, Via Modigliani 10, 20900 Monza, MB, Italy"},{"name":"Department of Medicine and Surgery, University of Milano Bicocca, 20126 Milan, MI, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Rinella, M.E., Lazarus, J.V., Ratziu, V., Francque, S.M., Sanyal, A.J., Kanwal, F., Romero, D., Abdelmalek, M.F., Anstee, Q.M., and Arab, J.P. (2023). A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol., 101133.","DOI":"10.1016\/j.aohep.2023.101133"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e2856","DOI":"10.1210\/clinem\/dgab262","article-title":"NAFLD and Liver Fibrosis Are Not Associated with Reduced Femoral Bone Mineral Density in the General US Population","volume":"106","author":"Ciardullo","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1002\/hep4.1969","article-title":"Impact of the new definition of metabolic dysfunction\u2013associated fatty liver disease on detection of significant liver fibrosis in US adolescents","volume":"6","author":"Ciardullo","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2337\/dc20-1778","article-title":"High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults with Type 2 Diabetes","volume":"44","author":"Ciardullo","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2337\/dc20-1997","article-title":"Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening","volume":"44","author":"Lomonaco","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: An updated meta-analysis of 501 022 adult individuals","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Mantovani, A., Dalbeni, A., Beatrice, G., Cappelli, D., and Gomez-Peralta, F. (2022). Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes. J. Clin. Med., 11.","DOI":"10.3390\/jcm11040968"},{"key":"ref_11","first-page":"1097","article-title":"Duration of type 2 diabetes and liver-related events in nonalcoholic fatty liver disease: A landmark analysis","volume":"10","author":"Zhang","year":"2023","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/j.gastro.2023.04.025","article-title":"Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People with Diabetes Versus People Without Diabetes: A Multicenter Study","volume":"165","author":"Huang","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1136\/gutjnl-2015-309265","article-title":"Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: A prospective cohort study","volume":"65","author":"Kwok","year":"2016","journal-title":"Gut"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.2337\/dc22-2048","article-title":"High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold","volume":"46","author":"Castera","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"109981","DOI":"10.1016\/j.diabres.2022.109981","article-title":"Prevalence of elevated liver stiffness in patients with type 1 and type 2 diabetes: A systematic review and meta-analysis","volume":"190","author":"Ciardullo","year":"2022","journal-title":"Diabetes Res. Clin. Prac."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association Between Fibrosis Stage and Outcomes of Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/ajg.2014.132","article-title":"Mortality from Chronic Liver Diseases in Diabetes","volume":"109","author":"Zoppini","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00592-021-01677-y","article-title":"Lack of awareness of liver organ damage in patients with type 2 diabetes","volume":"58","author":"Ciardullo","year":"2021","journal-title":"Acta Diabetol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Polanco-Briceno, S., Glass, D., Stuntz, M., and Caze, A. (2016). Awareness of nonalcoholic steatohepatitis and associated practice patterns of primary care physicians and specialists. BMC Res. Notes, 9.","DOI":"10.1186\/s13104-016-1946-1"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMra1610570","article-title":"Use of Liver Imaging and Biopsy in Clinical Practice","volume":"377","author":"Tapper","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/j.1572-0241.2001.03776.x","article-title":"Patient-Administered Nitrous Oxide\/Oxygen Inhalation Provides Safe and Effective Analgesia for Percutaneous Liver Biopsy: A Randomized Placebo-Controlled Trial","volume":"96","author":"Samii","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.cgh.2010.03.025","article-title":"Complication Rate of Percutaneous Liver Biopsies Among Persons with Advanced Chronic Liver Disease in the HALT-C Trial","volume":"8","author":"Seeff","year":"2010","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.22742","article-title":"Liver biopsy","volume":"49","author":"Rockey","year":"2009","journal-title":"Hepatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease","volume":"128","author":"Ratziu","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"Marchesini","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20142021 update","volume":"75","author":"Berzigotti","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/hep.24452","article-title":"Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis","volume":"54","author":"Hernaez","year":"2011","journal-title":"Hepatology"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., and Tiribelli, C. (2006). The Fatty Liver Index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol., 6.","DOI":"10.1186\/1471-230X-6-33"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig. Liver Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1053\/j.gastro.2009.06.005","article-title":"Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors","volume":"137","author":"Kotronen","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1007\/s00330-019-06072-4","article-title":"Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: A meta-analysis","volume":"29","author":"Gu","year":"2019","journal-title":"Eur. Radiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/hep.29639","article-title":"Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis","volume":"67","author":"Caussy","year":"2018","journal-title":"Hepatology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_36","unstructured":"FDA-NIH Biomarker Working Group (2016). BEST (Biomarkers, EndpointS, and other Tools) Resource."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e000904","DOI":"10.1136\/bmjdrc-2019-000904","article-title":"Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications","volume":"8","author":"Ciardullo","year":"2020","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s40618-020-01188-7","article-title":"Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD","volume":"43","author":"Ciardullo","year":"2020","journal-title":"J. Endocrinol. Investig."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1053\/j.gastro.2004.08.052","article-title":"Serum markers detect the presence of liver fibrosis: A cohort study","volume":"127","author":"Rosenberg","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_42","first-page":"303","article-title":"The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters","volume":"5","author":"Nielsen","year":"2013","journal-title":"Am. J. Transl. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1053\/j.gastro.2008.09.013","article-title":"Performance of ELF Serum Markers in Predicting Fibrosis Stage in Pediatric Non-Alcoholic Fatty Liver Disease","volume":"136","author":"Nobili","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jhep.2017.11.028","article-title":"Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions","volume":"68","author":"Loomba","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","article-title":"Noninvasive biomarkers in NAFLD and NASH\u2014current progress and future promise","volume":"15","author":"Wong","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive Assessment of Liver Disease in Patients with Nonalcoholic Fatty Liver Disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1002\/hep.28394","article-title":"Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy","volume":"63","author":"Cassinotto","year":"2016","journal-title":"Hepatology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.23312","article-title":"Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease","volume":"51","author":"Wong","year":"2010","journal-title":"Hepatology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.cgh.2018.12.031","article-title":"Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"European Association for Study of Liver (2015). EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J. Hepatol., 63, 237\u2013264.","DOI":"10.1016\/j.jhep.2015.04.006"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.mric.2014.05.001","article-title":"Magnetic Resonance Elastography of Liver","volume":"22","author":"Venkatesh","year":"2014","journal-title":"Magn. Reson. Imaging Clin. North Am."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1148\/radiol.2018170601","article-title":"Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions","volume":"286","author":"Kennedy","year":"2018","journal-title":"Radiology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","article-title":"Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease Than Transient Elastography","volume":"150","author":"Imajo","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1053\/j.gastro.2017.03.017","article-title":"American Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis","volume":"152","author":"Lim","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/hep.30842","article-title":"Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data from the STELLAR Trials","volume":"70","author":"Anstee","year":"2019","journal-title":"Hepatology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1007\/s00125-017-4264-9","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: Do they lead to over-referral?","volume":"60","author":"Blond","year":"2017","journal-title":"Diabetologia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-sponsored by the American Association for the Study of Liver Diseases (AASLD)","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr. Pract."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.2337\/dc23-S004","article-title":"4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1210\/jc.2015-1966","article-title":"High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels","volume":"100","author":"Bril","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Trenell","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hep.22009","article-title":"Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach","volume":"47","author":"Bellentani","year":"2007","journal-title":"Hepatology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1665-2681(19)31873-3","article-title":"Clinical update on non-alcoholic fatty liver disease and steatohepatitis","volume":"7","author":"Bugianesi","year":"2008","journal-title":"Ann. Hepatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40618-017-0799-3","article-title":"NAFLD\/NASH in patients with type 2 diabetes and related treatment options","volume":"41","author":"Radaelli","year":"2018","journal-title":"J. Endocrinol. Investig."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH","volume":"53","author":"Sumida","year":"2018","journal-title":"J. Gastroenterol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.diabet.2019.12.007","article-title":"Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials","volume":"46","author":"Mantovani","year":"2020","journal-title":"Diabetes Metab."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: A meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","article-title":"Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: A systematic review","volume":"7","author":"Mantovani","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): A substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_73","unstructured":"Sanyal, A.J. (2023, January 22\u201326). Retatrutide NAFLD\u2014Phase 2 trial results in subset of patients with obesity and NAFLD. Proceedings of the American Diabetes Association Meeting, San Diego, CA, USA."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: The role of peroxisome proliferator-activated receptors","volume":"18","author":"Francque","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1111\/liv.15005","article-title":"PPAR-\u03b3-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH","volume":"41","author":"Gastaldelli","year":"2021","journal-title":"Liver Int."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.dld.2021.04.029","article-title":"Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)","volume":"54","author":"Marchesini","year":"2022","journal-title":"Dig. Liver Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jhep.2015.11.031","article-title":"Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?","volume":"64","author":"Gastaldelli","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., and Targher, G. (2021). Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. Metabolites, 11.","DOI":"10.3390\/metabo11020073"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.dld.2021.07.013","article-title":"GLP-1 receptor agonists and reduction of liver fat content in NAFLD patients: Just a question of weight loss?","volume":"53","author":"Mantovani","year":"2021","journal-title":"Dig. Liver Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diabet.2019.01.008","article-title":"Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications","volume":"45","author":"Scheen","year":"2019","journal-title":"Diabetes Metab."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple\u2013Hormone-Receptor Agonist Retatrutide for Obesity\u2014A Phase 2 Trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","volume":"14","author":"Eslam","year":"2020","journal-title":"Hepatol. Int."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/17\/5597\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:40:29Z","timestamp":1760128829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/17\/5597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,27]]},"references-count":83,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["jcm12175597"],"URL":"https:\/\/doi.org\/10.3390\/jcm12175597","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,27]]}}}